Peer-influenced content. Sources you trust. No registration required. This is HCN.
Ophthalmology Management
Reproxalap is an investigational drug candidate for the treatment of dry eye disease.
Ophthalmology March 24th 2026
Conexiant
TECNIS PureSee IOL is the first and only US FDA‑approved extended depth of focus (EDOF) IOL with no warning on loss of contrast sensitivity
MDLinx
“There are a lot of people with autism who don’t have a folate deficiency, and there are a lot of people with a folate deficiency who don’t have autism.” — Ben Rein, PhD
Neurology March 18th 2026
Cardiology Advisor
The Wegovy tablet is the first oral GLP-1 receptor agonist indicated for weight loss and cardiovascular risk reduction in eligible adults.
Endocrinology & Diabetes Nursing March 13th 2026
Consultant360
“Today’s approval of the first generic fluticasone propionate inhalation aerosol represents an important step in expanding access to affordable asthma treatment.” – Iilun Murphy, MD, Director of the Office of Generic Drugs in the FDA’s Center for Drug Evaluation and Research
Allergy & Immunology March 12th 2026
Ophthalmology Advisor
The combined action of the drugs results in pupil constriction, resulting in a pinhole effect that improves near visual acuity and depth of focus in patients with presbyopia.
Ophthalmology March 9th 2026
DIET & NUTRITION 
PATIENT EDUCATION 
OBESITY/WEIGHT MANAGEMENT 
EXERCISE/TRAINING 
LEGAL MATTERS 
GUIDELINES/RECOMMENDATIONS